Study finds among outpatients with mild to moderate COVID-19, treatment with fluvoxamine does not reduce duration of symptoms Post author: Post published:November 22, 2023 Post category:uncategorized Researchers investigate the effects of high-dose fluvoxamine among patients with mild-to-moderate COVID-19. You Might Also Like Female bodybuilders face higher risk of sudden cardiac death, study reveals October 22, 2025 New therapeutic approach targets PCSK9 to regulate blood cholesterol levels June 11, 2025 Popular fad diets can pack a nutritional punch, new study reveals October 29, 2023